tuftsin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-08 and is reviewed periodically as new material appears.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or below | For lyophilized powder, long term |
| Common analytical method | Reverse-phase HPLC | Usually paired with mass spectrometry |
| Typical reported purity | At or above 95 percent by area | Research-grade material |
| Aqueous solubility | High | Solutions used in laboratory assays |
| Moisture sensitivity | Hydrolyzes in solution | Aseptic handling reduces degradation |
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
=== Cured meat and cheese industries === The bacteria L. lactis is the primary bacteria responsible for the ripening of cheeses, and the enzymes within the bacteria play key roles in the development of flavor, texture, and aroma profiles. The branched-chain amino acid aminotransferases help to produce compounds like isovaleric acid, isobutyric acid, 2- and 3-methylbutan(al)(ol) and 2-methylpropan(al)(ol) that impart fruity or malty aromas depending on the amount of compound present. Along with the aromatic aminotransferases (AraT), BCATs in L. lactis help develop the aroma/flavor resulting from volatile sulphur compounds produced during fermentation. The bacteria Staphylococcus carnosus and Enterococcus faecalis are often used in tandem with other lactic acid bacterium to begin the meat fermentation process. BCATs in these two bacteria perform transaminations during meat fermentation, producing the corresponding α-ketoacids from amino acids. As fermentation proceeds, these α-ketoacids degrade into a class of compounds known as methyl-branched volatiles that include aldehydes, alcohols, and carboxylic acids, all of which contribute to the distinct scents and flavors of cured meats.
=== Muscarinic agonists === Xanomeline/trospium chloride (Cobenfy) - A fixed-dose combination of xanomeline and trospium chloride. Xanomeline is a functionally selective muscarinic M4 and M1 receptor agonist. Trospium chloride is a peripherally-acting non-selective muscarinic antagonist. Xanomeline/trospium chloride was approved for medical use in the United States in September 2024.
Romania has attracted increasing amounts of foreign investment following the end of communism, with the stock of foreign direct investment (FDI) in Romania rising to €83.8 billion in June 2019. Romania's FDI outward stock (an external or foreign business either investing in or purchasing the stock of a local economy) amounted to $745 million in December 2018, the lowest value among the 28 EU member states. Since 1867 the official currency has been the Romanian leu ("lion"), which "was redenominated, with the exchange rate set at 1 new leu = 10,000 old lei" in 2005 according to the National Bank of Romania. As it joined the EU in 2007, Romania plans to adopt the euro in 2029.
According to the constitution of Greece, higher education institutions (HEI) include universities, technical universities, and specialist institutions. HEI undergraduate programs are government-funded and do not charge tuition. A quarter of HEI postgraduate programs are tuition-free. After individual assessments, thirty percent of Greek students are entitled to attend any of the statutory postgraduate programs without tuition fees. Founded as a national institution in 1926, the Academy of Athens is the highest research establishment in Greece. Private higher education institutions could not operate in Greece and were not recognized as degree-awarding bodies by the Greek government until the law 5094/2024 was passed in 2024, permitting the establishment and operation of private Higher Education Institutions (HEIs). Such HEIs are yet to be accredited and established.
Sources: en.wikipedia.org
In molecular biology, the leguminous lectin family is a family of lectin proteins. It is one of the largest lectin families with more than 70 lectins reported in a review in 1990. Leguminous lectins consist of two or four subunits, each containing one carbohydrate-binding site. The interaction with sugars requires tightly bound calcium and manganese ions. The structural similarities of these lectins are reported by the primary structural analyses and X-ray crystallographic studies. X-ray studies have shown that the folding of the polypeptide chains in the region of the carbohydrate-binding sites is also similar, despite differences in the primary sequences. The carbohydrate-binding sites of these lectins consist of two conserved amino acids on beta pleated sheets. One of these loops contains transition metals, calcium and manganese, which keep the amino acid residues of the sugar-binding site at the required positions. Amino acid sequences of this loop play an important role in the carbohydrate-binding specificities of these lectins. These lectins bind either glucose, mannose or galactose. The exact function of legume lectins is not known but they may be involved in the attachment of nitrogen-fixing bacteria to legumes and in the protection against pathogens. Some legume lectins are proteolytically processed to produce two chains, beta (which corresponds to the N-terminal) and alpha (C-terminal). The lectin concanavalin A (conA) from jack bean is exceptional in that the two chains are transposed and ligated (by formation of a new peptide bond).
IGC experiments are typically carried out at "infinite dilution", where only small amounts of probe molecule are injected. This region is also called Henry's law region or linear region of the sorption isotherm. At infinite dilution probe-probe interactions are assumed negligible and any retention is only due to probe-solid interactions. The resulting retention volume, VRo, is given by the following equation:
Pesticides include a wide variety of chemical compounds, used in both agriculture and non-agricultural contexts. Globally, roughly 4,000 chemical compounds are officially registered as being designed for biological activity as pesticides. Pesticides are broadly categorized into plant protection products for countering pests and diseases, and biocidal products such as disinfectants, which may be used domestically to control harmful organisms. Agricultural pesticides are further grouped into herbicides (used against plants), fungicides (used against fungi and spores), and insecticides (against insects). The properties targeted by pesticides are often shared by both the intended targets and other non-target species, including humans. Both those working with pesticides and those living near areas of application are at increased risk. Evidence from epidemiological, animal, and in vitro studies suggests that exposure to pesticides increases the risk for Parkinson's disease. Numerous meta‐analyses and epidemiological studies have reported an increased risk ratio or odds ratio for being exposed to pesticides. PD prevalence is associated with local pesticide use. Length of duration of pesticide exposure is associated with increased PD risk, while high proximity and frequent pesticide exposure are associated with earlier age of onset. Pesticide exposure after diagnosis may accelerate disease progression. Herbicides such as paraquat, diquat, rotenone and glyphosate are the most clearly established environmental toxicants for PD and are likely causal.
In the fields of medicine, biotechnology, and pharmacology, drug discovery is the process by which new drugs are discovered. Historically, drugs were discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery. Later chemical libraries of synthetic small molecules, natural products, or extracts were screened in intact cells or whole organisms to identify substances that have a desirable therapeutic effect in a process known as classical pharmacology. Since sequencing of the human genome which allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high throughput screening of large compound libraries against isolated biological targets which are hypothesized to be disease-modifying in a process known as reverse pharmacology. Hits from these screens are then tested in cells and then in animals for efficacy. Even more recently, scientists have been able to understand the shape of biological molecules at the atomic level and to use that knowledge to design (see drug design) drug candidates. Modern drug discovery involves the identification of screening hits, medicinal chemistry, and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, it will begin the process of drug development prior to clinical trials.
A laser microprobe mass spectrometer (LMMS), also laser microprobe mass analyzer (LAMMA), laser ionization mass spectrometer (LIMS), or laser ionization mass analyzer (LIMA) is a mass spectrometer that uses a focused laser for microanalysis. It employs local ionization by a pulsed laser and subsequent mass analysis of the generated ions.
Sources: en.wikipedia.org
This was also the belief of geologist Palmer, who convinced Steven Jones that the helium-3 occurring naturally in Earth perhaps came from fusion involving hydrogen isotopes inside catalysts like nickel and palladium. This led their team in 1986 to independently make the same experimental setup as Fleischmann and Pons (a palladium cathode submerged in heavy water, absorbing deuterium via electrolysis). Fleischmann and Pons had much the same belief, but they calculated the pressure to be of 1027 atmospheres, when cold fusion experiments achieve a loading ratio of only one to one, which has only between 10,000 and 20,000 atmospheres. John R. Huizenga says they had misinterpreted the Nernst equation, leading them to believe that there was enough pressure to bring deuterons so close to each other that there would be spontaneous fusions.
=== Notable cases === Dames & Moore v. Regan KindHearts for Charitable Humanitarian Development v. Geithner Genova Pipe v. Lutnick and Noem Learning Resources, Inc. v. Trump, and Trump v. V.O.S. Selections, Inc. Nintendo of America Inc. v. U.S. Department of the Treasury
Traceability: The ability to reconstruct the development history of a drug or medical device. Accountability: The ability to resolve who has contributed what to the development and when. Another version, ALCOA++, adds:
=== Supervoltage cancer therapy === Working from an auto garage near Harvard Square, HVEC began building Trump's gas-insulated Van de Graaff generators for hospitals and manufacturers. In 1947, the first orders came from several British hospitals for HVEC's compact 2-megavolt machines. The company was among the first to make artificial radiation sources commercially available for cancer treatment. After three years, HVEC had delivered 17 particle accelerators, employed 140 people, and negotiated $2 million in sales (equivalent to $27.1 million in 2025), eclipsing its competitors' products and undercutting them on price. Nevertheless, the company faced severe financial difficulties in its early years. On several occasions, technical problems brought HVEC to within days of exhausting both money and credit. By the mid-1950s, successor technologies like cobalt-60 machines built by General Electric began dominating hospital orders, offering simpler operation and lower maintenance costs. Although HVEC remained in the medical market until 1969, the company increasingly focused on redesigning its generators for research and industrial applications.
Sources: en.wikipedia.org
The most common approach combines reverse-phase liquid chromatography with mass spectrometry. Chromatography separates the components while mass spectrometry confirms the molecular mass. Peptide sequencing or tandem mass analysis can further verify the amino acid order.
Lyophilized powder is usually kept frozen and protected from moisture. Solutions are less stable and are often used promptly or divided into aliquots to avoid repeated freeze-thaw cycles. Exact shelf-life values depend on purity and handling.
No. A purity figure derived from chromatographic area does not prove the amino acid sequence. Identity requires an orthogonal method such as mass spectrometry or sequencing. Truncated or isomerized peptides can co-elute with the target compound.
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.